137 related articles for article (PubMed ID: 27380637)
1. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
Bossuyt V; Symmans WF
Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Bossuyt V; Provenzano E; Symmans WF; Boughey JC; Coles C; Curigliano G; Dixon JM; Esserman LJ; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Viale G; Cameron D;
Ann Oncol; 2015 Jul; 26(7):1280-91. PubMed ID: 26019189
[TBL] [Abstract][Full Text] [Related]
3. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients.
Bossuyt V; Spring L
Breast J; 2020 Jun; 26(6):1189-1198. PubMed ID: 32468652
[TBL] [Abstract][Full Text] [Related]
4. Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
Bossuyt V
Surg Pathol Clin; 2018 Mar; 11(1):213-230. PubMed ID: 29413658
[TBL] [Abstract][Full Text] [Related]
5. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
[TBL] [Abstract][Full Text] [Related]
6. The Perfect Pathology Report After Neoadjuvant Therapy.
Marchiò C; Maletta F; Annaratone L; Sapino A
J Natl Cancer Inst Monogr; 2015 May; 2015(51):47-50. PubMed ID: 26063886
[TBL] [Abstract][Full Text] [Related]
7. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
9. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
Tetzlaff MT; Messina JL; Stein JE; Xu X; Amaria RN; Blank CU; van de Wiel BA; Ferguson PM; Rawson RV; Ross MI; Spillane AJ; Gershenwald JE; Saw RPM; van Akkooi ACJ; van Houdt WJ; Mitchell TC; Menzies AM; Long GV; Wargo JA; Davies MA; Prieto VG; Taube JM; Scolyer RA
Ann Oncol; 2018 Aug; 29(8):1861-1868. PubMed ID: 29945191
[TBL] [Abstract][Full Text] [Related]
10. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges.
See SHC; Siziopikou KP
Pathol Res Pract; 2022 Feb; 230():153753. PubMed ID: 34990870
[TBL] [Abstract][Full Text] [Related]
11. Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances.
Mrkonjic M; Berman HK; Done SJ; Youngson B; Mulligan AM
J Clin Pathol; 2019 Feb; 72(2):120-132. PubMed ID: 30670564
[TBL] [Abstract][Full Text] [Related]
12. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.
Sahoo S; Lester SC
Arch Pathol Lab Med; 2009 Apr; 133(4):633-42. PubMed ID: 19391665
[TBL] [Abstract][Full Text] [Related]
13. [GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting].
Maran-Gonzalez A; Franchet C; Duprez-Paumier R; Antoine M; Barlier C; Becette V; Berghian A; Blanc-Fournier C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Fleury C; Garbar C; Ghnassia JP; Haudebourg J; MacGrogan G; Mathieu MC; Michenet P; Penault-Llorca F; Poulet B; Robin Y; Roger P; Russ E; Treilleux I; Valent A; Verriele V; Vincent-Salomon A; Arnould L; Lacroix-Triki M;
Ann Pathol; 2019 Dec; 39(6):383-398. PubMed ID: 31257035
[TBL] [Abstract][Full Text] [Related]
14. Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement.
Guerini-Rocco E; Botti G; Foschini MP; Marchiò C; Mastropasqua MG; Perrone G; Roz E; Santinelli A; Sassi I; Galimberti V; Gianni L; Viale G
Tumori; 2022 Jun; 108(3):196-203. PubMed ID: 34918596
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
16. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
[TBL] [Abstract][Full Text] [Related]
17. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
Provenzano E; Bossuyt V; Viale G; Cameron D; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Boughey J; Curigliano G; Dixon JM; Esserman L; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Symmans WF;
Mod Pathol; 2015 Sep; 28(9):1185-201. PubMed ID: 26205180
[TBL] [Abstract][Full Text] [Related]
18. Lack of Standardization in the Processing and Reporting of Post-Neoadjuvant Breast Cancer Specimens.
Han R; Regpala S; Slodkowska E; Nofech-Mozes S; Hanna W; Parra-Herran C; Lu FI
Arch Pathol Lab Med; 2020 Oct; 144(10):1262-1270. PubMed ID: 32142368
[TBL] [Abstract][Full Text] [Related]
19. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
Sahoo S; Krings G; Chen YY; Carter JM; Chen B; Guo H; Hibshoosh H; Reisenbichler E; Fan F; Wei S; Khazai L; Balassanian R; Klein ME; Shad S; Venters SJ; Borowsky AD; Symmans WF; Ocal IT
Arch Pathol Lab Med; 2022 May; 147(5):591-603. PubMed ID: 35976643
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy.
Fontanella C; Loibl S; von Minckwitz G
Breast; 2015 Nov; 24 Suppl 2():S84-7. PubMed ID: 26279131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
